In a study, Abbott's Perclose had 9.3% access-site complications; LockeT had 1.2%.

Catheter Precision, a subsidiary of Flyte Aviation (VJET), published a study in The Journal of Interventional Cardiology comparing its LockeT device to Abbott's Perclose. LockeT showed fewer complications (1.2% vs. 9.3%) and zero device failures, while both had similar hemostasis times. LockeT is FDA-registered and CE Mark-approved, sold in the US, Europe, and South America.

Original reporting
Published Oct 22, 2026, 8:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 9:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$ABT
Bearish
medium confidence
Mentioned
$ABT · $VJET
Relevance
6/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ABTBearishLow
01

Why it matters

The study provides fresh safety data that could shift clinician preference and affect sales expectations for both Abbott and Flyte Aviation's medical subsidiary.

02

Market read

First disclosure of comparative clinical data may influence device adoption and affect stock sentiment for Abbott (ABT) and Flyte Aviation (VJET).

03

What to watch

Regulatory approvals, reimbursement policies, and adoption rates will ultimately determine market impact.

Relevance 6/10Novelty 6/10Timing: today

Background

The press release announces the first peer‑reviewed comparative study of a new suture retention device (LockeT) versus Abbott's established Perclose VCD, highlighting lower complication rates for LockeT.

Company-level read

Ticker impact

$ABTBearishMedium confidence
Context

Abbott's Perclose device showed 9.3% access-site complications versus 1.2% for the competing LockeT device in a newly published study.

Expected impact

likely downside as clinicians may prefer the lower-complication LockeT device.

Evidence & confidence

The study is the first public disclosure of comparative safety data, which could affect market perception of Abbott's vascular closure product line.

$VJETBullishMedium confidence
Context

Flyte Aviation's subsidiary Catheter Precision released the study showing its LockeT device outperforms Abbott's Perclose.

Expected impact

potential upside as the study may drive demand for LockeT and raise visibility for Flyte Aviation's medical segment.

Evidence & confidence

First disclosure of favorable trial results for the LockeT device could boost investor sentiment toward the parent company.

Market effects

May influence the broader vascular closure device market and encourage competition.

U.S. and European medical device markets could see increased interest in suture retention technologies.

Limited to medical device sector; no broad macro impact.

Counterpoint

Investors may view the study as a niche finding with limited commercial impact on Abbott's overall portfolio.

Key entities

  • Abbott Laboratories

    Manufacturer of the Perclose vascular closure device.

  • Flyte Aviation, Inc.

    Parent company of Catheter Precision, which developed the LockeT device.

  • Catheter Precision

    Subsidiary of Flyte Aviation that created the LockeT suture retention device.

Related articles

$VJETMed

Flyte Aviation Reports Record Third Quarter 2026 Aviation Revenue Increasing 145% Sequentially

Flyte Aviation, Inc. (VJET) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Flyte Aviation Reports Record Third Quarter 2026 Aviation Revenue Increasing 145% Sequentially Flight Hours Surge 129% Sequentially; Flyte Fleet Fulfills More Than 99% of Customer Flights Three Additional Jets Expected to Begin Revenue Service in Q4, Expanding Fleet

$VJETMed

Flyte Aviation Reports Record Third Quarter 2026 Aviation Revenue Increasing 145% Sequentially

Flyte Aviation (VJET) reported record Q3 2026 revenue of $1.84M, up 145% sequentially. Flight hours surged 129%, with 99% of flights fulfilled in-house. The company plans to add three jets in Q4, expanding fleet capacity. CEO David Jenkins highlighted growth in international markets and digital booking. MedTech segment revenue rose 4% sequentially and 24% year-over-year to $280K, but is held for sale.

$ABTMed

Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

Abbott's (ABT) Medical Devices segment saw 8% sales growth in Q3 2026, driven by Electrophysiology (EP) products. EP sales grew mid-to-high-teens globally and over 20% in the U.S. Volt PFA catheter adoption accelerated post-U.S. launch. Abbott received FDA approval for TactiFlex Duo and CE Mark for Amulet 360. Japan launch expected in Q4. LAA market weakness is a headwind. Thermo Fisher (TMO) and Insulet (PODD) also reported Q3 earnings.

$ABTMed

Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?

Abbott's UltiSynq defibrillation lead received FDA and CE Mark approvals, backed by successful trial results. The device aims to improve cardiac rhythm management, with 98.5% successful implantation and 97.5% complication-free rate at three months. Abbott also received FDA's breakthrough device designation. Medtronic and Boston Scientific provided updates on their cardiac devices. Abbott shares have declined 12.2% over the past year, trading at a forward P/S of 3.60X.

$ABTMedAI 9/10

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.